Amgen granted FDA priority review designation for denosumab BLA Amgen today announced that the U.

Concern review designation can be granted to drugs that offer major advances in treatment, or give a treatment where no sufficient therapy exists. Related StoriesNew RNA test of blood platelets may be used to detect location of cancerCrucial switch in single DNA bottom predisposes children to aggressive type of cancerStudy shows rare HER2 missense mutations usually do not spread breasts cancer by themselves Many cancer sufferers with skeletal metastases suffer debilitating complications, despite receiving the best available therapies, said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Analysis and Development at Amgen.The primary efficacy endpoint is founded on DUS peak systolic velocity ratio . Many secondary efficacy endpoints were evaluated. The lack of stent fracture was also evaluated at both sites at the 6 and 12 month visits using regular x-ray evaluation methods. The pooled clinical results from the Auckland and Leipzig sites were 92.3 percent patency and a 0 percent fracture rate for the average lesion length of 86.8 mm. Both sites reported only one in-stent stenosis with 13 individuals at each site for a total of 26 sufferers at half a year to-date. Freedom from Major Adverse Cardiac Events at both sites was 100 percent. Dr. William Gray, Director of Endovascular Intervention at NY Columbia-Presbyterian Medical center in the Center for Interventional Vascular Therapy, will commence in early 2010..